# Meliolabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meliolabs

- Industry: Medical Devices & Equipment
- Headquarters: Santa Clara, US
- Website: www.melio.tech
- Latest round: Seed (Aug 26, 2022)
- Investors on record: 1

## About

Based in California, US, and founded by its CEO, Mridu Sinha, Stephanie Fraley, and Shelley Lawrence, Meliolabs Inc., operates as a developer of artificial intelligence-powered sequence profiling platform to identify blood-based pathogens using a novel DNA melting technique. In January 2025, Meliolabs Inc. received USD 3.5 million of grant funding from new investor CARB-X. The company offers an artificial intelligence-based instrument platform that identifies blood-based pathogens. The devices use novel DNA melting techniques to provide end-to-end integrated user workflow serving medical and diagnostic laboratories.

The company plans to utilize the January 2025 funding to support the development of its diagnostic platform for detecting neonatal sepsis.

## Funding rounds

- Seed, Aug 26, 2022 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed